JP2011521981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521981A5 JP2011521981A5 JP2011512000A JP2011512000A JP2011521981A5 JP 2011521981 A5 JP2011521981 A5 JP 2011521981A5 JP 2011512000 A JP2011512000 A JP 2011512000A JP 2011512000 A JP2011512000 A JP 2011512000A JP 2011521981 A5 JP2011521981 A5 JP 2011521981A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- substituted
- alkyl
- het
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 230000003073 embolic effect Effects 0.000 claims description 2
- -1 cyclic amine Chemical class 0.000 claims 40
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 15
- 125000002947 alkylene group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 13
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 235000019260 propionic acid Nutrition 0.000 claims 9
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000006239 protecting group Chemical group 0.000 claims 5
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- OIDOVTVIWNAVJY-NJYVYQBISA-N (2r)-3-(2-aminoethylsulfonyl)-2-[[(3r,6s)-4-oxo-6-propan-2-yl-8,13-dioxa-5-azabicyclo[12.2.2]octadeca-1(16),14,17-trien-3-yl]carbamoylamino]propanoic acid Chemical compound C1[C@@H](NC(=O)N[C@@H](CS(=O)(=O)CCN)C(O)=O)C(=O)N[C@@H](C(C)C)COCCCCOC2=CC=C1C=C2 OIDOVTVIWNAVJY-NJYVYQBISA-N 0.000 claims 1
- ZVEVQADHVAIPND-XPWALMASSA-N (2s)-3-(6-aminopyridin-3-yl)-2-[[(3r,6s)-4-oxo-6-propan-2-yl-8,13-dioxa-5-azabicyclo[12.2.2]octadeca-1(16),14,17-trien-3-yl]carbamoylamino]propanoic acid Chemical compound C([C@H](NC(=O)N[C@@H]1CC2=CC=C(C=C2)OCCCCOC[C@@H](NC1=O)C(C)C)C(O)=O)C1=CC=C(N)N=C1 ZVEVQADHVAIPND-XPWALMASSA-N 0.000 claims 1
- IZDLTKHIFLHDDA-JQHSSLGASA-N (2s)-3-(6-aminopyridin-3-yl)-2-[[(3s,6r)-3-methyl-5-oxo-1-oxa-4-azacyclotetradec-6-yl]carbamoylamino]propanoic acid Chemical compound O=C1N[C@@H](C)COCCCCCCCC[C@H]1NC(=O)N[C@H](C(O)=O)CC1=CC=C(N)N=C1 IZDLTKHIFLHDDA-JQHSSLGASA-N 0.000 claims 1
- DHYQTBANMOAJLV-IXDOHACOSA-N (2s)-3-(6-aminopyridin-3-yl)-2-[[(3s,6r)-5,9-dioxo-3-propan-2-yl-1-oxa-4,10-diazacyclotridec-6-yl]carbamoylamino]propanoic acid Chemical compound O=C1N[C@@H](C(C)C)COCCCNC(=O)CC[C@H]1NC(=O)N[C@H](C(O)=O)CC1=CC=C(N)N=C1 DHYQTBANMOAJLV-IXDOHACOSA-N 0.000 claims 1
- OPTOXSVCVQEIKN-HSALFYBXSA-N (2s)-3-(6-aminopyridin-3-yl)-2-[[(3s,6r)-5-oxo-3-propan-2-yl-1-oxa-4-azacyclotetradec-6-yl]carbamoylamino]propanoic acid Chemical compound O=C1N[C@@H](C(C)C)COCCCCCCCC[C@H]1NC(=O)N[C@H](C(O)=O)CC1=CC=C(N)N=C1 OPTOXSVCVQEIKN-HSALFYBXSA-N 0.000 claims 1
- LULOJIQVOUOYMX-BHDDXSALSA-N (2s)-6-amino-2-[[(3r,6s)-4-oxo-6-propan-2-yl-8,13-dioxa-5-azabicyclo[12.2.2]octadeca-1(16),14,17-trien-3-yl]carbamoylamino]hexanoic acid Chemical compound C1[C@@H](NC(=O)N[C@@H](CCCCN)C(O)=O)C(=O)N[C@@H](C(C)C)COCCCCOC2=CC=C1C=C2 LULOJIQVOUOYMX-BHDDXSALSA-N 0.000 claims 1
- UHDSHGDMNRMYEP-BHDDXSALSA-N (2s)-6-amino-2-[[(3r,6s)-4-oxo-6-propan-2-yl-8,13-dioxa-5-azabicyclo[12.2.2]octadeca-1(16),14,17-trien-3-yl]sulfamoylamino]hexanoic acid Chemical compound C1[C@@H](NS(=O)(=O)N[C@@H](CCCCN)C(O)=O)C(=O)N[C@@H](C(C)C)COCCCCOC2=CC=C1C=C2 UHDSHGDMNRMYEP-BHDDXSALSA-N 0.000 claims 1
- QXXFIOYJSRYYSJ-JIMJEQGWSA-N (2s)-6-amino-2-[[(3r,6s)-4-oxo-6-propan-2-yl-8,17-dioxa-5-azabicyclo[16.2.2]docosa-1(20),18,21-trien-3-yl]carbamoylamino]hexanoic acid Chemical compound C1[C@@H](NC(=O)N[C@@H](CCCCN)C(O)=O)C(=O)N[C@@H](C(C)C)COCCCCCCCCOC2=CC=C1C=C2 QXXFIOYJSRYYSJ-JIMJEQGWSA-N 0.000 claims 1
- FQONWTZXYFYCBR-ARFHVFGLSA-N (2s)-6-amino-2-[[(3s,6r)-5-oxo-3-propan-2-yl-1,8-dioxa-4-azacyclododec-6-yl]carbamoylamino]hexanoic acid Chemical compound CC(C)[C@H]1COCCCCOC[C@@H](NC(=O)N[C@@H](CCCCN)C(O)=O)C(=O)N1 FQONWTZXYFYCBR-ARFHVFGLSA-N 0.000 claims 1
- JSGVAFDSUVDMJG-CEXWTWQISA-N (2s)-6-amino-2-[[(3s,6r)-5-oxo-3-propan-2-yl-1-oxa-4-azacyclotetradec-6-yl]carbamoylamino]hexanoic acid Chemical compound CC(C)[C@H]1COCCCCCCCC[C@@H](NC(=O)N[C@@H](CCCCN)C(O)=O)C(=O)N1 JSGVAFDSUVDMJG-CEXWTWQISA-N 0.000 claims 1
- ALMMBDDTZHEVOE-TYRYEOGQSA-N (2s)-6-amino-2-[[(3s,6s)-4-oxo-6-propan-2-yl-8,13-dioxa-5-azabicyclo[12.2.2]octadecan-3-yl]carbamoylamino]hexanoic acid Chemical compound C1[C@H](NC(=O)N[C@@H](CCCCN)C(O)=O)C(=O)N[C@@H](C(C)C)COCCCCOC2CCC1CC2 ALMMBDDTZHEVOE-TYRYEOGQSA-N 0.000 claims 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 1
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims 1
- SMXQWQOLIUDIHX-HOGRCIIVSA-N C1[C@@H](NC(=O)N[C@@H](CCCCN)C(O)=O)C(=O)N[C@@H](C(C)C)COCC(O)C(O)COC2=CC=C1C=C2 Chemical compound C1[C@@H](NC(=O)N[C@@H](CCCCN)C(O)=O)C(=O)N[C@@H](C(C)C)COCC(O)C(O)COC2=CC=C1C=C2 SMXQWQOLIUDIHX-HOGRCIIVSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 230000005526 G1 to G0 transition Effects 0.000 claims 1
- 241000406668 Loxodonta cyclotis Species 0.000 claims 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims 1
- 125000002785 azepinyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004069 aziridinyl group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 125000004623 carbolinyl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 claims 1
- 238000001212 derivatisation Methods 0.000 claims 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 125000003838 furazanyl group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 claims 1
- 125000005438 isoindazolyl group Chemical group 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 claims 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 claims 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 claims 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 230000009863 secondary prevention Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 claims 1
- 229940125670 thienopyridine Drugs 0.000 claims 1
- 239000002175 thienopyridine Substances 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290520 | 2008-06-06 | ||
| EP08290520.9 | 2008-06-06 | ||
| PCT/EP2009/003650 WO2009146802A1 (de) | 2008-06-06 | 2009-05-22 | Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521981A JP2011521981A (ja) | 2011-07-28 |
| JP2011521981A5 true JP2011521981A5 (OSRAM) | 2014-04-10 |
| JP5531011B2 JP5531011B2 (ja) | 2014-06-25 |
Family
ID=39800716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512000A Expired - Fee Related JP5531011B2 (ja) | 2008-06-06 | 2009-05-22 | ＴＡＦＩａの阻害剤としての大環状尿素およびスルファミド誘導体 |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US8580777B2 (OSRAM) |
| EP (1) | EP2300462B1 (OSRAM) |
| JP (1) | JP5531011B2 (OSRAM) |
| KR (1) | KR101673886B1 (OSRAM) |
| CN (1) | CN102056922B (OSRAM) |
| AR (1) | AR072007A1 (OSRAM) |
| AU (1) | AU2009254257B2 (OSRAM) |
| BR (1) | BRPI0913349A2 (OSRAM) |
| CA (1) | CA2726554C (OSRAM) |
| CL (1) | CL2009001358A1 (OSRAM) |
| CO (1) | CO6321271A2 (OSRAM) |
| CR (1) | CR11807A (OSRAM) |
| CY (1) | CY1115604T1 (OSRAM) |
| DK (1) | DK2300462T3 (OSRAM) |
| DO (1) | DOP2010000363A (OSRAM) |
| EC (1) | ECSP10010655A (OSRAM) |
| ES (1) | ES2494390T3 (OSRAM) |
| HN (1) | HN2010002558A (OSRAM) |
| HR (1) | HRP20140787T1 (OSRAM) |
| IL (1) | IL209772A (OSRAM) |
| MA (1) | MA32322B1 (OSRAM) |
| MX (1) | MX2010012793A (OSRAM) |
| NI (1) | NI201000203A (OSRAM) |
| NZ (1) | NZ589671A (OSRAM) |
| PL (1) | PL2300462T3 (OSRAM) |
| PT (1) | PT2300462E (OSRAM) |
| RU (1) | RU2502736C2 (OSRAM) |
| SI (1) | SI2300462T1 (OSRAM) |
| SV (1) | SV2010003747A (OSRAM) |
| TW (1) | TWI455928B (OSRAM) |
| UA (1) | UA104002C2 (OSRAM) |
| UY (1) | UY31868A (OSRAM) |
| WO (1) | WO2009146802A1 (OSRAM) |
| ZA (1) | ZA201007719B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA104002C2 (ru) | 2008-06-06 | 2013-12-25 | Санофи-Авентис | МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa |
| KR20110025970A (ko) | 2008-06-23 | 2011-03-14 | 아스트라제네카 아베 | 트롬빈 억제제로서 사용하기 위한 신규 복소환 카복스아미드 |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| PT2822953T (pt) * | 2012-03-06 | 2017-04-06 | Pfizer | Derivados macrocíclicos para o tratamento de doenças proliferativas |
| JP6461113B2 (ja) * | 2013-06-10 | 2019-01-30 | サノフイＳａｎｏｆｉ | ＴＡＦＩａの阻害剤としての大環状尿素誘導体、それらの製造および医薬としての使用 |
| UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| CN103755852B (zh) * | 2013-12-18 | 2015-12-09 | 湖北大学 | 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途 |
| CN106631832A (zh) * | 2016-10-08 | 2017-05-10 | 帕潘纳(北京)科技有限公司 | 一种氨基醚类化合物的制备方法 |
| US10411291B2 (en) * | 2017-03-22 | 2019-09-10 | Nanotek Instruments, Inc. | Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU667995B2 (en) | 1993-02-15 | 1996-04-18 | Bayer Aktiengesellschaft | New pseudopeptides having an antiviral action |
| TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| US5888971A (en) * | 1996-02-20 | 1999-03-30 | Ortho Pharmaceutical Corporation, Inc. | Macrocyclic peptides useful in the treatment of thrombin related disorders |
| WO1999011606A2 (en) | 1997-08-28 | 1999-03-11 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
| US6124278A (en) * | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
| US6482921B1 (en) | 1999-01-28 | 2002-11-19 | Essential Therapeutics, Inc. | Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use |
| EP1130022B1 (en) * | 2000-02-29 | 2009-07-22 | Universita Degli Studi di Firenze | 3-Aza-6,8-dioxabicyclo[3.2.1]octanes and analogues and combinatorial libraries containing them |
| DE102004020186A1 (de) * | 2004-04-22 | 2005-11-17 | Aventis Pharma Deutschland Gmbh | Heterocyclylessigsäuren als Inhibitoren von TAFla |
| KR20090087044A (ko) | 2006-12-06 | 2009-08-14 | 사노피-아벤티스 | ＴＡＦＩａ 억제제로서의 요소 및 설파미드 유도체 |
| UA104002C2 (ru) | 2008-06-06 | 2013-12-25 | Санофи-Авентис | МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa |
-
2009
- 2009-05-22 UA UAA201100191A patent/UA104002C2/ru unknown
- 2009-05-22 WO PCT/EP2009/003650 patent/WO2009146802A1/de not_active Ceased
- 2009-05-22 MX MX2010012793A patent/MX2010012793A/es active IP Right Grant
- 2009-05-22 EP EP09757185.5A patent/EP2300462B1/de active Active
- 2009-05-22 AU AU2009254257A patent/AU2009254257B2/en not_active Ceased
- 2009-05-22 DK DK09757185T patent/DK2300462T3/da active
- 2009-05-22 PL PL09757185T patent/PL2300462T3/pl unknown
- 2009-05-22 HR HRP20140787AT patent/HRP20140787T1/hr unknown
- 2009-05-22 SI SI200931001T patent/SI2300462T1/sl unknown
- 2009-05-22 NZ NZ589671A patent/NZ589671A/en not_active IP Right Cessation
- 2009-05-22 KR KR1020107027133A patent/KR101673886B1/ko not_active Expired - Fee Related
- 2009-05-22 RU RU2010154089/04A patent/RU2502736C2/ru not_active IP Right Cessation
- 2009-05-22 US US12/996,460 patent/US8580777B2/en not_active Expired - Fee Related
- 2009-05-22 BR BRPI0913349A patent/BRPI0913349A2/pt not_active Application Discontinuation
- 2009-05-22 CA CA 2726554 patent/CA2726554C/en not_active Expired - Fee Related
- 2009-05-22 ES ES09757185.5T patent/ES2494390T3/es active Active
- 2009-05-22 PT PT09757185T patent/PT2300462E/pt unknown
- 2009-05-22 CN CN2009801210767A patent/CN102056922B/zh not_active Expired - Fee Related
- 2009-05-22 JP JP2011512000A patent/JP5531011B2/ja not_active Expired - Fee Related
- 2009-06-04 AR ARP090102005 patent/AR072007A1/es unknown
- 2009-06-04 UY UY31868A patent/UY31868A/es not_active Application Discontinuation
- 2009-06-04 CL CL2009001358A patent/CL2009001358A1/es unknown
- 2009-06-04 TW TW98118477A patent/TWI455928B/zh not_active IP Right Cessation
-
2010
- 2010-10-28 ZA ZA2010/07719A patent/ZA201007719B/en unknown
- 2010-11-22 NI NI201000203A patent/NI201000203A/es unknown
- 2010-11-23 DO DO2010000363A patent/DOP2010000363A/es unknown
- 2010-11-23 CR CR11807A patent/CR11807A/es not_active Application Discontinuation
- 2010-11-30 MA MA33377A patent/MA32322B1/fr unknown
- 2010-12-01 CO CO10151420A patent/CO6321271A2/es active IP Right Grant
- 2010-12-02 EC ECSP10010655 patent/ECSP10010655A/es unknown
- 2010-12-02 SV SV2010003747A patent/SV2010003747A/es unknown
- 2010-12-03 HN HN2010002558A patent/HN2010002558A/es unknown
- 2010-12-05 IL IL209772A patent/IL209772A/en not_active IP Right Cessation
-
2013
- 2013-10-08 US US14/048,339 patent/US8722655B2/en not_active Expired - Fee Related
-
2014
- 2014-03-26 US US14/226,132 patent/US9126955B2/en not_active Expired - Fee Related
- 2014-08-08 CY CY20141100631T patent/CY1115604T1/el unknown
-
2015
- 2015-07-28 US US14/811,364 patent/US9309207B2/en not_active Expired - Fee Related
-
2016
- 2016-03-01 US US15/057,920 patent/US9688645B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521981A5 (OSRAM) | ||
| CN113557235B (zh) | 用于药物治疗的杂环化合物 | |
| AU2019262144B2 (en) | RIP1 inhibitory compounds and methods for making and using the same | |
| EP1411932B1 (de) | Kombinationstherapie substituierter oxazolidinone | |
| EP3860989B1 (en) | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors | |
| CN106518924B (zh) | 用于治疗nk-1受体相关疾病的取代的4-苯基吡啶 | |
| EP3713926B1 (en) | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists | |
| CN104379576B (zh) | 作为因子xia抑制剂用于治疗血栓栓塞疾病的取代的吡咯烷 | |
| RU2701156C9 (ru) | Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах | |
| EP2515902A1 (en) | Analogues for the treatment or prevention of flavivirus infections | |
| AU2019351494A1 (en) | Nitroxoline prodrug and use thereof | |
| WO2015043364A1 (zh) | 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物 | |
| KR101673886B1 (ko) | ＴＡＦＩａ의 억제제로서의 마크로사이클릭 우레아 및 술파미드 유도체 | |
| EA006443B1 (ru) | Ингибиторы трипептидил пептидазы | |
| CA2660166C (fr) | Nouveaux derives imidazolones, leur preparation a titre de medicaments, compositions pharmaceutiques, utilisation comme inhibiteurs de proteines kinases notamment cdc7 | |
| EA003426B1 (ru) | Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции | |
| EP3022193B1 (en) | Inhibitors of leukotriene production | |
| TW591031B (en) | Thienopyridine derivatives, their production and use | |
| ES2355164T3 (es) | Nuevo método para la preparación de sales de amonio de esomeprazol. | |
| EP4649086A1 (en) | Protease inhibitors for treating or preventing coronavirus infection | |
| EP3022194B1 (en) | Inhibitors of leukotriene production | |
| CA2795877A1 (en) | Novel sultam compounds | |
| JPH10175977A (ja) | 縮合インドール誘導体、その製造法及び用途 | |
| CN104876950A (zh) | 一种含硫稠杂四环氮杂糖衍生物及其制备方法和应用 | |
| JPH02193996A (ja) | １，２，３，４―テトラヒドロアクリジンの縮合複素環状誘導体 |